Imprint Wealth LLC Has $808,000 Stake in Eli Lilly and Company (NYSE:LLY)

Imprint Wealth LLC decreased its position in Eli Lilly and Company (NYSE:LLY) by 49.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,375 shares of the company’s stock after selling 1,349 shares during the period. Imprint Wealth LLC’s holdings in Eli Lilly and Company were worth $808,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. JGP Wealth Management LLC lifted its holdings in Eli Lilly and Company by 0.9% during the 4th quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock valued at $1,074,000 after purchasing an additional 16 shares during the last quarter. Cassia Capital Partners LLC boosted its holdings in shares of Eli Lilly and Company by 1.8% during the 3rd quarter. Cassia Capital Partners LLC now owns 951 shares of the company’s stock worth $511,000 after buying an additional 17 shares during the period. Walkner Condon Financial Advisors LLC grew its stake in Eli Lilly and Company by 2.8% in the 3rd quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company’s stock valued at $334,000 after buying an additional 17 shares during the last quarter. Patton Albertson Miller Group LLC raised its holdings in Eli Lilly and Company by 2.8% in the 3rd quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock valued at $335,000 after acquiring an additional 17 shares during the period. Finally, Valley Wealth Managers Inc. lifted its position in Eli Lilly and Company by 1.3% during the third quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock worth $688,000 after acquiring an additional 17 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Truist Financial reaffirmed a “buy” rating and issued a $850.00 price objective on shares of Eli Lilly and Company in a report on Friday, March 22nd. Bank of America lifted their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Barclays raised their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Finally, BMO Capital Markets increased their price target on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Trading Down 0.6 %

Shares of NYSE:LLY traded down $4.68 during midday trading on Tuesday, hitting $746.09. 852,929 shares of the stock were exchanged, compared to its average volume of 3,062,083. The business’s 50-day moving average price is $762.68 and its 200 day moving average price is $655.54. Eli Lilly and Company has a 12 month low of $367.35 and a 12 month high of $800.78. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The stock has a market capitalization of $708.90 billion, a price-to-earnings ratio of 128.77, a P/E/G ratio of 1.65 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same quarter in the previous year, the firm posted $2.09 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 28.1% on a year-over-year basis. Analysts predict that Eli Lilly and Company will post 12.46 earnings per share for the current year.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 54,032 shares of the stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the completion of the sale, the insider now directly owns 99,488,598 shares in the company, valued at approximately $64,177,109,911.86. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.